Life Science Outsourcing, Inc.

Life Science Outsourcing, Inc. Life Science Outsourcing is a performance-driven contract manufacturer helping medical device and pharmaceutical innovators start up, speed up, and scale up.

LSO’s services and capabilities provide you with an opportunity to focus on running your business, while we provide turnkey manufacturing, testing, validation, sterilization and distribution services. Our primary focus is to assist you in reaching your corporate objectives and ultimate success in the medical marketplace.

The global IVD contract manufacturing market hit $21.1 billion in 2024. Most of that growth runs through one hard proble...
09/07/2026

The global IVD contract manufacturing market hit $21.1 billion in 2024. Most of that growth runs through one hard problem: turning a bench assay into a validated, auditable manufacturing line.

We put together a detailed walkthrough of how that actually works, covering cleanroom class selection, process validation under ISO 13485:2016 Clause 7.5.6, lot-release panel design, supply-chain controls for critical biologicals, and how to structure the quality agreement so your DHF holds up under audit.

https://lso-inc.com/news/scaling-diagnostic-consumable-manufacturing-603d63ad/

A practical guide to scaling IVD consumables: cleanroom class, process validation, lot release, supply chain, and the CM QMS-to-DHF interface.

FDA stopped using QSIT on February 2, 2026. Inspections now run under Compliance Program 7382.850, and if your mock-insp...
09/01/2026

FDA stopped using QSIT on February 2, 2026. Inspections now run under Compliance Program 7382.850, and if your mock-inspection scripts are still built around the four old subsystems, they're auditing to a framework that no longer applies.

The bigger gap for most OEMs: the records for outsourced processes like packaging validation and sterilization validation sit at contract facilities, not in your own four walls. That evidence still has to be retrievable on the day an investigator walks in.

Our latest article maps exactly where the exposure is and what to do about it.

https://lso-inc.com/news/qmsr-inspection-readiness-mapping-what-auditors-want-276fd0ac/

QSIT is retired and FDA now inspects under Compliance Program 7382.850. Here is how to map QMSR inspection readiness across your supply chain.

Two seals can show the same peel-force number and mean completely different things, depending on which ASTM F88 support ...
08/31/2026

Two seals can show the same peel-force number and mean completely different things, depending on which ASTM F88 support technique was used to generate it.

Technique A (free-tail), B (90°), or C (180°) each produce different values from the same seal. They're not interchangeable, and ISO 11607-1 won't set your acceptance criteria for you. That part is on you to define and justify.

Our latest article covers grip setup, jaw breaks, slippage, and how F88 data connects to your validation package.

https://lso-inc.com/news/astm-f88-peel-testing-for-medical-packaging-025f5f2e/

How to set up ASTM F88 seal-strength testing — fixture configuration, grip speed, jaw breaks, slippage, and mapping peel force to ISO 11607-1 criteria.

The QMSR took effect February 2, 2026, and it changed more than clause numbers. FDA can now inspect records that were of...
08/24/2026

The QMSR took effect February 2, 2026, and it changed more than clause numbers. FDA can now inspect records that were off-limits under the old QSR: internal audit reports, management-review minutes, supplier audit reports. A CM still quoting retired 21 CFR 820 subparts in your next supplier audit is telling you something important about how it will perform in an FDA inspection.

We put together a clause-by-clause crosswalk and a practical checklist of what to verify before you qualify your next contract manufacturer.

https://lso-inc.com/news/qmsr-audit-prep-what-investigators-expect-from-your-cm-dfea941d/

Under the QMSR, familiar QSR anchors now live as ISO 13485 clauses and more records are inspectable. What OEM quality teams should verify in their CM.

As of February 2, 2026, FDA's Quality System Regulation was replaced by the QMSR, which incorporates ISO 13485:2016 by r...
08/21/2026

As of February 2, 2026, FDA's Quality System Regulation was replaced by the QMSR, which incorporates ISO 13485:2016 by reference and makes it enforceable federal law. If your procedures still cite design controls at 820.30 or purchasing at 820.50, you're referencing removed text. The requirements didn't disappear. They moved to ISO 13485:2016 Clauses 7.3, 7.4, and 4.1. For OEMs that outsource manufacturing, Clause 4.1 is the one to focus on. It makes outsourced-process control an inspectable part of your quality system, not just a supplier management formality.

https://lso-inc.com/news/the-qmsr-era-what-changed-for-oems-and-their-cms-3964d3b8/

The QMSR took effect February 2, 2026, folding ISO 13485:2016 into FDA's quality framework. What it means for OEM quality systems and CM oversight.

ISO 13485 certification does not exempt your contract manufacturer from an FDA inspection. Under QMSR, which took effect...
08/17/2026

ISO 13485 certification does not exempt your contract manufacturer from an FDA inspection. Under QMSR, which took effect February 2, 2026, your supplier qualification records fall squarely within scope for a 7382.850 inspection.

That means Clause 7.4 purchasing controls, on-site audit observations, and your quality agreement all need to hold up when an investigator arrives. Our latest article walks through what to request before the audit, what to watch on the floor, and how to write an agreement that leaves no ambiguity.

https://lso-inc.com/news/qualifying-and-auditing-a-cm-under-qmsr-87700a19/

A quality director's guide to qualifying and auditing a contract manufacturer under QMSR: ISO 13485 Clause 7.4 controls, pre-audit docs, and agreements.

Two of the three top early QMSR Form 483 observation areas are supplier-facing: outsourcing/purchasing and risk manageme...
08/17/2026

Two of the three top early QMSR Form 483 observation areas are supplier-facing: outsourcing/purchasing and risk management. That's not a coincidence. Under the QMSR, supplier audit reports and corrective-action files that FDA couldn't previously pull are now reviewable during an inspection. If your supplier files show open findings without closure evidence, an inspector can see that now.

Our latest article covers what actually changed, where early observations are clustering, and how to use the transition window to harden supplier controls before the next inspection.

https://lso-inc.com/news/qmsr-readiness-what-changes-and-what-auditors-want-3d0a2457/

The QMSR took effect February 2, 2026. Here's what changed under 21 CFR Part 820, where early 483s are clustering, and how to harden supplier quality systems.

No standard tells you which cleanroom class your device requires. ISO 14644-1 defines the classes. Your risk assessment ...
08/14/2026

No standard tells you which cleanroom class your device requires. ISO 14644-1 defines the classes. Your risk assessment defines which one you need, and skipping that step is how teams end up paying for ISO 5 when ISO 8 would hold up fine in an audit.

Our new decision guide walks the process in order: start with device risk under ISO 13485:2016 Clause 6.4, design the room and the flow around it, build a monitoring program that proves it holds, and know what to ask when you're qualifying a contract manufacturer's cleanroom.

https://lso-inc.com/news/cleanroom-assembly-for-medical-devices-a-decision-guide-17c3d14a/

How to select an ISO 14644 class by device risk, design assembly and gowning flow, monitor under ISO 13485 Clause 6.4, and qualify a CM cleanroom.

The prototype usually isn't what breaks when you scale a microfluidic cartridge from 50 units to 50,000. The process is....
08/13/2026

The prototype usually isn't what breaks when you scale a microfluidic cartridge from 50 units to 50,000. The process is.

Bonding method, critical dimensions, cleanroom class, and lot-release criteria are the four decisions that determine whether scale-up goes cleanly or generates expensive scrap. Under the QMSR, ISO 13485:2016 Clauses 6.4, 7.5.6, and 8.2.6 are the operative requirements covering each one. We walk through all four and why they have to be sequenced correctly.

https://lso-inc.com/news/scaling-microfluidic-cartridge-assembly-to-volume-5773f3b9/

How IVD teams scale microfluidic cartridge assembly: bonding method selection, critical dimensions, cleanroom controls, and lot-release testing.

Three Impella recalls. Three different failure types. Only two belong in an assembly-gate conversation.The perforation-r...
07/27/2026

Three Impella recalls. Three different failure types. Only two belong in an assembly-gate conversation.

The perforation-risk action was an IFU correction, not an assembly failure. No leak test on the line would have caught it. But the introducer leak and the out-of-spec SmartAssist units? Those are exactly what defined acceptance gates are built to stop.

We broke down what the public record says, what it doesn't say, and the questions every OEM should ask a contract manufacturer before a sealed-device program ramps.

https://lso-inc.com/news/impella-recalls-what-oems-learn-about-assembly-gates-32369e13/

The Abiomed Impella recalls show how cleanroom process gaps become public FDA events, and how defined assembly gates keep introducer leak defects off the market.

Address

830 Challenger Street
Brea, CA
92821

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

(714) 672-1090

Website

Alerts

Be the first to know and let us send you an email when Life Science Outsourcing, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share